title: Stage I testicular tumours: the Tata Memorial Hospital experience.
abstract: One hundred and fifty-six patients with stage I testicular germ cell tumours--81 seminomas and 75 nonseminomatous tumours--were treated at the Tata Memorial Hospital, Bombay over a 5 year period. Among the seminomas, 71 were treated with post-orchidectomy prophylactic radiation therapy to the retroperitoneum and/or mediastinum, while 10 patients refused radiation therapy and were put on surveillance. The disease-free and total survival in seminomas were 92.6% and 100%, respectively. Among the patients with nonseminomatous tumours, 58 had normal levels of serum biomarkers while 17 had raised biomarkers. In the normal marker group, 20 patients underwent retroperitoneal lymph node dissection (RPLND) with a nodal positivity of 30%, while the other 38 patients refused surgery and were either placed on unplanned surveillance (33 patients) or chemotherapy (5 patients). In this group, the patients undergoing RPLND had a survival rate of 100% as compared to 93.9% in those with surveillance. The overall disease-free and total survival rates in patients with normal markers were 86.2% and 96.6%, respectively. In the raised marker group, 6 patients underwent RPLND with a survival rate of 100% and 11 patients received chemotherapy with a survival of 90%, with the overall survival for patients with raised markers being 94.1%. The overall disease-free and total survival rates for all patients with stage I nonseminomatous tumours were 88% and 96%, respectively.
authors.affiliation: Department of Uro-Oncology, Tata Memorial Hospital, Bombay, India.
authors.forename: H B
authors.initials: HB
authors.lastname: Tongaonkar
authors.forename: A V
authors.initials: AV
authors.lastname: Dalal
authors.forename: D S
authors.initials: DS
authors.lastname: Kelkar
authors.forename: J N
authors.initials: JN
authors.lastname: Kulkarni
authors.forename: M R
authors.initials: MR
authors.lastname: Kamat
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis; D003131:Combined Modality Therapy; D018237:Germinoma / Q000556:secondary / Q000628:therapy*; D006801:Humans; D007194:India; D008297:Male; D018239:Seminoma / Q000628:therapy; D016019:Survival Analysis; D013736:Testicular Neoplasms / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor